Publication date: Nov 10, 2024
Background NVX-CoV2373, a recombinant SARS-CoV-2 spike (rS) protein vaccine with Matrix-M adjuvant, has been authorized for use in adults and adolescents. PREVENT-19 (NCT04611802/2019nCoV-301), a pivotal phase 3, randomized, placebo-controlled trial demonstrated robust efficacy of a primary, 2-dose series of NVX-CoV2373 against COVID-19. Methods Protocol expansions to PREVENT-19 included enrollment of adolescents (aged 12 to
| Concepts | Keywords |
|---|---|
| 15042024_jn1_ure | Cov |
| Gay | Cov2373 |
| German | Covid |
| Vaccinated | Dose |
| Editing | |
| Https | |
| Medrxiv | |
| Novavax | |
| Nvx | |
| Preprint | |
| Reviewing | |
| Sars | |
| Vaccine | |
| Vaccines | |
| Writing |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | protein |
| disease | MESH | COVID-19 |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | assay |
| disease | MESH | seroconversion |
| disease | MESH | urticaria |
| disease | MESH | breakthrough infection |
| disease | IDO | symptom |
| disease | MESH | infection |
| disease | MESH | complications |
| disease | IDO | replication |
| disease | IDO | country |
| disease | MESH | Allergy |
| disease | MESH | AIDS |
| drug | DRUGBANK | Carboxyamidotriazole |
| disease | IDO | blood |
| disease | MESH | emergency |
| drug | DRUGBANK | Adenosine 5′-phosphosulfate |
Download Document
(Visited 1 times, 1 visits today)